A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors

AGX101 is an antibody-drug conjugate (ADC) therapy for tumor-forming cancers. The purpose of this study is to learn about AGX101 effects and safety at various dose levels in an all-comers advanced solid cancer patient population. AGX101will be administered intravenously. Dosing of AGX101 will be repeated once every 3, 6 or 9 weeks. Participants may continue study treatment until disease progression, unacceptable toxicity, or consent withdrawal. Subjects will attend an end of treatment visit and will receive two safety follow-up telephone contacts up to 90 days following the last dose of study

Trial Details

NCT ID
NCT06440005
Phase
PHASE1
Sponsor
Angiex, Inc.
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • AGX101
Locations (sample)
  • Los Angeles, California, United States|34.05223,-118.24368
  • Sarasota, Florida, United States|27.33643,-82.53065
  • St Louis, Missouri, United States|38.62727,-90.19789
  • Nashville, Tennessee, United States|36.16589,-86.78444
  • San Antonio, Texas, United States|29.42412,-98.49363

Key Eligibility Criteria

  • Histologically confirmed unresectable, locally advanced, or metastatic solid tumors.
  • Refractory to or relapsed after all standard therapies known to provide proven clinical benefit, unless the patient is not a candidate for standard…
  • Willing to authorize use of existing archival tissue, unless otherwise discussed with Sponsor
  • Time since the last dose of prior therapy to treat underlying malignancy (including other investigational therapy): Systemic cytotoxic chemotherapy…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →